Comparison of Serum Myokine Dosages and Imaging Methods in the Evaluation of Sarcopenia in Patients With Hepatocellular Carcinoma

Recruiting now · Not applicable

Conditions studied: Sarcopenia, Hepatocellular Carcinoma

In brief

It is known that some substances present in the blood, called 'myokines,' influence muscle loss. Some may accelerate this loss, while others may prevent it. Inflammatory substances in the blood can also contribute to muscle loss. Sarcopenia is assessed by an imaging technique called 'Skeletal Muscle Mass Index (SMI)' to measure muscle mass. This analysis can be done from radiological examinations. Sarcopenia has a serious impact on patients with hepatocellular carcinoma. It increases the risk of death, cancer recurrence, and decreases the response to treatments. Therefore, the investigators want to determine if blood tests for myokines obtained by simple blood draw can improve the assessment of sarcopenia in this specific setting.

Key facts

Study ID

NCT06475118

Run by

CHU de Reims

People needed

139

Starts

2024-11-22

Expected to finish

2026-05-22

Last updated by the study team

2024-11-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• New diagnosis of HCC made by radiology and/or histopathology according to EASL criteria, regardless of the degree of hepatic fibrosis (METAVIR F0-F4)
• Availability of a pre-therapeutic three-phase contrast-enhanced abdominal-pelvic CT scan.
• Non-inclusion criteria:
• Presence of an active cancer other than HCC
• Uncontrolled HIV infection.

Where it is running

• Damien JOLLY — Reims, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.